EVALUATION OF RENAL FUNCTION AND RENAL RISK
IN THE TWENTY-FIRST CENTURY
CME course of the DIABESITY working group
Villa Camozzi, Ranica-Bergamo, Italy September-October 2015

Day 1: EVALUATION OF RENAL FUNCTION

8:30 Introduction: How are we assessing renal function? (Irene van del Meer, Holland)

8:45 Lecture: “Measurement of renal function: 30 years of experience in the Mario Negri Institute” (G Remuzzi)

CLINICAL ASPECTS OF THE BIAS OF ESTIMATED GFR IN NEPHROLOGY

9:30 “Glomerular hyperfiltration: its role in renal disease” (C.E. Mogensen)

10:00 “Are we detecting hyperfiltration and changes in renal function in diabetes? (P. Ruggenenti)

10:30 “Obesity and renal disease” (M. Praga)

11:00 Coffee break

11:30 “Do formulas detect the impact of weight reduction in changes of renal function in obesity: the CRESO experience” (Manuela Abate)

12:00 “Adjusting for body surface area, a misleading procedure” (Pierre Delanaye or Christophe Mariat, Liege-Belgium)

12:30 “Can we really evaluate the evolution of chronic nephropathies with formulas” (Norberto Perico)

12:30 “Renal and non-renal transplantation” (Mads Hornum)

13:00 Lunch break
WHY FORMULAS FAIL?

14:00 The (unappreciated) role of cystatin C in metabolic syndrome and its impact in renal function estimation (A De Vries).

14:30 Is creatinine enough to reflect renal function? (E. Porrini)

BEYOND NEPHROLOGY

15:00 “Consequences of using estimated GFR in drug dosing and drug monitoring” (Bo Feldt-Rasmussen)

METHODOLOGICAL ASPECTS

15:30 "Clinical trials in Nephrology: which outcome, measured or estimated GFR“ (Annalisa Perna)

16:00 “How to evaluate a formula” Introduction to agreement methods for continuous measurements (Lawrence Lin or J Bland or Douglas Altman)

16:30 "Diverse methods to measure GFR in humans and animals" (F. Gaspari)

17:00 Coffee break

17:30-19:00 ABSTRACTS SESSION

19:30 Concluding remarks: (Aiko De Vries)

20:00 DINNER
Day 2: EVALUATION OF RENAL RISK IN DIABETES AND OBESITY

8:30 Overview: markers or renal disease in diabetes and obesity, where do we stand? (Radovan Hojs)

ALBUMINURIA

9:00 Glomerular and tubular handling of albuminuria. (C Zoja, or Sangalli F)

9:30 Albuminuria as a marker of cardiovascular disease in T2DM (E. Porrini)

10:00 Albuminuria, a marker of renal disease: the pathologist perspective (M. Abbate or Ingebor Bajema)

TUBULAR MARKERS

10:30 Markers of fatty kidney: liver-type fatty acid binding protein (L-FABP) and free fatty acids as (Juan Gómez-Gerique, Santander-Spain)

11:00 New markers of tubular damage in diabetic nephropathy: kidney injury marker 1 (KIM-1), acetyl-β-d-glucosaminidasa (NGAL), α1 microglobulina. (Rossing P to be confirmed)

11:30 Coffee break

INFLAMMATORY MARKERS

12:00 Is diabetic nephropathy an inflammatory disease? (Peter Senvinkell-or Juan Jesus Carrero; Sweden)

12:30 Urinary inflammatory markers in the follow-up of diabetic nephropathy? (Juan Navarro-Spain)

13:00 Lunch